Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
Celcuity (NASDAQ:CELC), a clinical-stage biotechnology company focused on targeted oncology therapies, has scheduled a conference call and webcast for July 28, 2025, at 8:00 AM ET to present topline results from the PIK3CA Wild-Type Cohort of their Phase 3 VIKTORIA-1 trial in HR+/HER2- advanced breast cancer.
The management team will host the presentation with a live webcast available, and participants can register for the teleconference in advance. A replay will be accessible on Celcuity's website after the event.
Celcuity (NASDAQ:CELC), un'azienda biotecnologica in fase clinica specializzata in terapie oncologiche mirate, ha programmato una conference call e una diretta web per il 28 luglio 2025 alle 8:00 AM ET per presentare i risultati principali della coorte PIK3CA Wild-Type del loro trial di Fase 3 VIKTORIA-1 nel carcinoma mammario avanzato HR+/HER2-.
Il team dirigenziale condurrà la presentazione con una diretta web disponibile, e i partecipanti possono registrarsi in anticipo per la teleconferenza. Una registrazione sarà accessibile sul sito di Celcuity dopo l'evento.
Celcuity (NASDAQ:CELC), una empresa biotecnológica en fase clínica centrada en terapias oncológicas dirigidas, ha programado una llamada de conferencia y una transmisión en vivo para el 28 de julio de 2025 a las 8:00 AM ET para presentar los resultados principales de la cohorte PIK3CA Wild-Type de su ensayo de Fase 3 VIKTORIA-1 en cáncer de mama avanzado HR+/HER2-.
El equipo directivo realizará la presentación con una transmisión en vivo disponible, y los participantes pueden registrarse previamente para la teleconferencia. Una repetición estará disponible en el sitio web de Celcuity después del evento.
Celcuity (NASDAQ:CELC)는 표적 항암 치료제에 중점을 둔 임상 단계의 생명공학 회사로, 2025년 7월 28일 오전 8시(동부 시간)에 HR+/HER2- 진행성 유방암 대상 3상 VIKTORIA-1 시험의 PIK3CA 야생형 코호트 주요 결과를 발표하기 위해 컨퍼런스 콜과 웹캐스트를 예정했습니다.
경영진이 발표를 주최하며 실시간 웹캐스트가 제공되며, 참가자는 사전에 전화 회의 등록이 가능합니다. 이벤트 후 Celcuity 웹사이트에서 다시보기를 이용할 수 있습니다.
Celcuity (NASDAQ:CELC), une société biotechnologique en phase clinique spécialisée dans les thérapies oncologiques ciblées, a programmé une conférence téléphonique et une webdiffusion pour le 28 juillet 2025 à 8h00 ET afin de présenter les résultats principaux de la cohorte PIK3CA Wild-Type de leur essai de phase 3 VIKTORIA-1 dans le cancer du sein avancé HR+/HER2-.
L'équipe de direction animera la présentation avec une webdiffusion en direct disponible, et les participants peuvent s'inscrire à la téléconférence à l'avance. Une rediffusion sera accessible sur le site web de Celcuity après l'événement.
Celcuity (NASDAQ:CELC), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf zielgerichtete Onkologie-Therapien, hat eine Telefonkonferenz und Webcast für den 28. Juli 2025 um 8:00 Uhr ET angesetzt, um die wichtigsten Ergebnisse der PIK3CA Wild-Type Kohorte ihrer Phase-3-Studie VIKTORIA-1 bei fortgeschrittenem HR+/HER2- Brustkrebs vorzustellen.
Das Management-Team wird die Präsentation leiten, die als Live-Webcast verfügbar sein wird, und Teilnehmer können sich im Voraus für die Telefonkonferenz registrieren. Eine Aufzeichnung wird nach der Veranstaltung auf der Celcuity-Website abrufbar sein.
- None.
- None.
MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.
Webcast and Conference Call Information
The Celcuity management team will host a webcast/conference call on Monday, July 28, 2025 at 8:00 a.m. ET to discuss the topline results from the Phase 3 VIKTORIA-1 trial. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com
(415) 513-1284
FAQ
When will Celcuity (CELC) announce the VIKTORIA-1 Phase 3 trial results?
What is the VIKTORIA-1 trial studying for Celcuity (CELC)?
How can investors access Celcuity's VIKTORIA-1 trial results presentation?
What type of breast cancer is being targeted in Celcuity's VIKTORIA-1 trial?
